{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:53:19Z","timestamp":1791139999868,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1093\/neuonc\/not154","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T20:36:38Z","timestamp":1386275798000},"page":"310-317","source":"Crossref","is-referenced-by-count":152,"title":["Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas\u2014a Pediatric Brain Tumor Consortium study"],"prefix":"10.1093","volume":"16","author":[{"given":"Sridharan","family":"Gururangan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Fangusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Young","family":"Poussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger E.","family":"McLendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Onar-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Gilbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Vajapeyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Jakacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Gajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian F.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry S.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Boyett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Fouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry E.","family":"Kun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,12,4]]},"reference":[{"issue":"9","key":"key\n\t\t\t\t20170508162907_NOT154C1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s003810100496","article-title":"Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification","volume":"17","author":"Rickert","year":"2001","journal-title":"Childs Nerv Syst"},{"key":"key\n\t\t\t\t20170508162907_NOT154C2","article-title":"CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004\u20132005. Source: Central Brain Tumor Registry of the United States, 2009. www.cbtrus.org","author":"CBTRUS"},{"issue":"2","key":"key\n\t\t\t\t20170508162907_NOT154C3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/srao.2001.21421","article-title":"Multidisciplinary management of pediatric low-grade gliomas","volume":"11","author":"Watson","year":"2001","journal-title":"Seminars in Radiation Oncol"},{"issue":"5","key":"key\n\t\t\t\t20170508162907_NOT154C4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3171\/jns.1997.86.5.0747","article-title":"Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas","volume":"86","author":"Packer","year":"1997","journal-title":"J Neurosurg"},{"issue":"3","key":"key\n\t\t\t\t20170508162907_NOT154C5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11060-005-6754-8","article-title":"Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma","volume":"75","author":"Perilongo","year":"2005","journal-title":"J Neurooncol"},{"issue":"12","key":"key\n\t\t\t\t20170508162907_NOT154C6","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","article-title":"Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma","volume":"30","author":"Bouffet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170508162907_NOT154C7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"key\n\t\t\t\t20170508162907_NOT154C8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2990.2011.01160.x","article-title":"Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells","volume":"37","author":"Sikkema","year":"2011","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"7","key":"key\n\t\t\t\t20170508162907_NOT154C9","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1365-2990.2010.01113.x","article-title":"Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma: is it much different from glioblastoma?","volume":"36","author":"Sie","year":"2010","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"key\n\t\t\t\t20170508162907_NOT154C10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/mpo.10308","article-title":"Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood","volume":"41","author":"Gesundheit","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"key\n\t\t\t\t20170508162907_NOT154C11","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/nrd1727","article-title":"Bevacizumab","author":"Ellis","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"18","key":"key\n\t\t\t\t20170508162907_NOT154C12","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2009.26.8789","article-title":"Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study","volume":"28","author":"Gururangan","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"key\n\t\t\t\t20170508162907_NOT154C13","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/neuonc\/nos213","article-title":"Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma\u2014a Pediatric Brain Tumor Consortium study","volume":"14","author":"Gururangan","year":"2012","journal-title":"Neuro Oncol"},{"issue":"5","key":"key\n\t\t\t\t20170508162907_NOT154C14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/pbc.24297","article-title":"Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas","volume":"60","author":"Hwang","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"key\n\t\t\t\t20170508162907_NOT154C15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pbc.21935","article-title":"Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan","volume":"52","author":"Packer","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"key\n\t\t\t\t20170508162907_NOT154C16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/JCO.2007.13.3652","article-title":"Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan","volume":"26","author":"Sathornsumetee","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"key\n\t\t\t\t20170508162907_NOT154C17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1634\/theoncologist.12-6-713","article-title":"FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist"},{"issue":"4","key":"key\n\t\t\t\t20170508162907_NOT154C18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrc2346","article-title":"Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer","volume":"8","author":"Jain","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"key\n\t\t\t\t20170508162907_NOT154C19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","article-title":"A perivascular niche for brain tumor stem cells","volume":"11","author":"Calabrese","year":"2007","journal-title":"Cancer Cell"},{"issue":"2","key":"key\n\t\t\t\t20170508162907_NOT154C20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1215\/15228517-2006-030","article-title":"Temozolomide in children with progressive low-grade glioma","volume":"9","author":"Gururangan","year":"2007","journal-title":"Neuro Oncol"},{"issue":"5","key":"key\n\t\t\t\t20170508162907_NOT154C21","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","article-title":"Irinotecan therapy in adults with recurrent or progressive malignant glioma","volume":"17","author":"Friedman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"29","key":"key\n\t\t\t\t20170508162907_NOT154C22","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1200\/JCO.2007.11.6103","article-title":"Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study","volume":"25","author":"Bomgaars","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"key\n\t\t\t\t20170508162907_NOT154C23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"issue":"4","key":"key\n\t\t\t\t20170508162907_NOT154C24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/neuonc\/noq206","article-title":"Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab","volume":"13","author":"Ellingson","year":"2011","journal-title":"Neuro Oncol"},{"issue":"30","key":"key\n\t\t\t\t20170508162907_NOT154C25","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2006.10.5825","article-title":"Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170508162907_NOT154C26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-009-9922-4","article-title":"The value of positron emission tomography and proliferation index in predicting progression in low-grade astrocytomas of childhood","volume":"95","author":"Kruer","year":"2009","journal-title":"J Neurooncol"},{"issue":"12","key":"key\n\t\t\t\t20170508162907_NOT154C27","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"issue":"2","key":"key\n\t\t\t\t20170508162907_NOT154C28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"issue":"23","key":"key\n\t\t\t\t20170508162907_NOT154C29","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"key\n\t\t\t\t20170508162907_NOT154C30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2007.11.9230","article-title":"Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study","volume":"26","author":"Glade Bender","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"key\n\t\t\t\t20170508162907_NOT154C31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170508162907_NOT154C32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/01926230600611836","article-title":"Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate","volume":"34","author":"Hall","year":"2006","journal-title":"Toxicologic pathology"},{"key":"key\n\t\t\t\t20170508162907_NOT154C33","article-title":"Avastin\u2122 Product safety information","author":"GenenTech Corporation","year":"2011"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/16\/2\/310\/16664772\/not154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T16:29:37Z","timestamp":1503505777000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/not154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,4]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,12,4]]},"published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/not154","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12,4]]}}}